Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
de Vries EGE, Rüschoff J, Lolkema M, Tabernero J, Gianni L, Voest E, de Groot DJA, Castellano D, Erb G, Naab J, Donica M, Deurloo R, van der Heijden MS, Viale G. de Vries EGE, et al. Cancer Med. 2023 Jun;12(11):12071-12083. doi: 10.1002/cam4.5893. Epub 2023 Apr 29. Cancer Med. 2023. PMID: 37119523 Free PMC article. Clinical Trial.
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, Nooij MA, Voest EE, Hupperets P, van Tinteren H, Peterse HL, TenVergert EM, de Vries EG; Netherlands Working Party on Autologous Transplantation in Solid Tumors. Rodenhuis S, et al. N Engl J Med. 2003 Jul 3;349(1):7-16. doi: 10.1056/NEJMoa022794. N Engl J Med. 2003. PMID: 12840087 Free article. Clinical Trial.
Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement.
Faneyte IF, Peterse JL, Van Tinteren H, Pronk C, Bontenbal M, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Ten Vergert EM, de Vries EG, Rodenhuis S, van de Vijver MJ. Faneyte IF, et al. Clin Cancer Res. 2004 Jul 1;10(13):4457-63. doi: 10.1158/1078-0432.CCR-03-0054. Clin Cancer Res. 2004. PMID: 15240537 Clinical Trial.
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study.
Nieboer P, Buijs C, Rodenhuis S, Seynaeve C, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Mulder NH, van der Graaf WT, TenVergert EM, van Tinteren H, de Vries EG. Nieboer P, et al. J Clin Oncol. 2005 Nov 20;23(33):8296-304. doi: 10.1200/JCO.2005.10.167. Epub 2005 Oct 11. J Clin Oncol. 2005. PMID: 16219926 Clinical Trial.
Theranostics Using Antibodies and Antibody-Related Therapeutics.
Moek KL, Giesen D, Kok IC, de Groot DJA, Jalving M, Fehrmann RSN, Lub-de Hooge MN, Brouwers AH, de Vries EGE. Moek KL, et al. Among authors: de vries ege, de groot dja. J Nucl Med. 2017 Sep;58(Suppl 2):83S-90S. doi: 10.2967/jnumed.116.186940. J Nucl Med. 2017. PMID: 28864618 Free article. Review.
89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake.
Moek KL, Waaijer SJH, Kok IC, Suurs FV, Brouwers AH, Menke-van der Houven van Oordt CW, Wind TT, Gietema JA, Schröder CP, Mahesh SVK, Jorritsma-Smit A, Lub-de Hooge MN, Fehrmann RSN, de Groot DJA, de Vries EGE. Moek KL, et al. Among authors: de vries ege, de groot dja. Clin Cancer Res. 2019 Jun 15;25(12):3517-3527. doi: 10.1158/1078-0432.CCR-18-2918. Epub 2019 Feb 11. Clin Cancer Res. 2019. PMID: 30745297
ESMO-MCBS: setting the record straight.
Cherny NI, Tabernero J, de Vries EGE. Cherny NI, et al. Among authors: de vries ege. Lancet Oncol. 2019 Apr;20(4):e192. doi: 10.1016/S1470-2045(19)30174-3. Lancet Oncol. 2019. PMID: 30942179 No abstract available.
552 results